Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Diarrhea
  • Neoplasm Recurrence, Local
  • Receptor, ErbB-2

abstract

  • Dose-dense AC followed by PTL and then followed by TL was not feasible because of a high rate of lapatinib dose reduction, mostly caused by unacceptable grade 3 diarrhea. Lapatinib (1,000 mg/d) was not feasible combined with weekly PT.

publication date

  • June 20, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3664034

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.26.5900

PubMed ID

  • 20479410

Additional Document Info

start page

  • 2982

end page

  • 8

volume

  • 28

number

  • 18